Breaking News on Contract Research, Manufacturing & Clinical Trials

Top Headlines

Clinical trials data: what companies need to know about transparency

As the European Medicines Agency (EMA) announces final consultations on its clinical trial data policy will begin at the start of May, we take a look at the issues surrounding trial transparency in Europe.

Related news

News in brief

CRO Quintiles has signed a five-year agreement to use OmniComm Systems' technology for Phase I clinic automation. 

Swiss high potency active pharmaceutical ingredient (API) contractor Cerbios has broken ground on a building that will bring together its chemical and biological R&D departments.

AMRI says its long-term outlook remains positive with continued demand for its contract research services despite plans to shutter a Discovery and Development Services (DDS) facility.

Consultancy and drug developer Certara has acquired specialty contract research organization (CRO) Synchrogenix Information Strategies, which offers regulatory writing and related services to biopharma and medical device companies worldwide. 

Global Industry News

FDA ‘breakthrough’ scheme approves GSK biologic, but is it faster? from BioPharma-Reporter.com

The US Food and Drug Administration (FDA) has approved a second “Breakthrough Therapy” biologic but it is still unclear whether the programme speeds drugs to market, says an expert.

INFOGRAPHIC

AZ for $100bn? Pfizer could buy Azerbaijan and keep the change from in-PharmaTechnologist.com

With Pfizer rumoured to be on the brink of a mega-merger with AstraZeneca, in-Pharmatechnologist.com brings you an interactive view of what £60bn ($101bn) could get.

Sanofi sells therapy cells: Aastrom buys products and plants from BioPharma-Reporter.com

Aastrom Biosciences will pay Sanofi $6.5m (EUR4.7m) for its cell therapy business in a deal that gives the cash strapped regenerative medicines developer three commercial products.

Big Pharma pull out and share slump won’t silence RNAi advocates from in-PharmaTechnologist.com

RNA interference (RNAi) developers that saw stock prices fall after Novartis pulled out of the market last week have reiterated their belief in the therapeutic and revenue potential of gene silencing drugs. 

AbbVie inks Humira packaging deal as it launches in Saudi Arabia from BioPharma-Reporter.com

AbbVie has teamed up with Arabio for the secondary packaging of its blockbuster biologic Humira as part of a launch into Saudi Arabian market.

Hospira announces two US recalls due to manufacturing, supplier issues from in-PharmaTechnologist.com

Hospira has announced US recalls for seven lots of its propofol injection and one lot of 1% Lidocaine HCI Injection due to a glass contamination.

Spotlight

Biotech and pipeline refills add to preclinical turnaround, say analysts

Biotech and pipeline refills add to preclinical turnaround, say analysts

Demand from biotech firms and Big Pharma’s need to refill its pipeline is driving the preclinical services...

Drugmakers start your engines: GSK's Formula One discovery formula

Drugmakers start your engines: GSK's Formula One discovery formula

GSK has asked Formula One team Mclaren to help it discover drugs, arguing that Big Data expertise...

AmerisourceBergen to launch $100m distribution JV in Brazil

AmerisourceBergen to launch $100m distribution JV in Brazil

AmerisourceBergen (ABC) plans to buy a minority stake in a Brazilian drug wholesaler and outlined plans for...

AMRI to acquire CDMO Cedarburg for $41M

AMRI to acquire CDMO Cedarburg for $41M

AMRI will acquire Cedarburg Pharmaceuticals for $38.2m (€27.7) in cash, plus $2.8m of assumed liabilities, to expand...

Evotec buys academic asset management specialist

Evotec buys academic asset management specialist

Evotec AG has bought an asset management company that specialises in bringing academic discovery and development innovations...

Key Industry Events

 

Access all events listing

Our events, Events from partners...